Earlier vasopressin may help septic shock

Early vasopressin may improve some septic shock outcomes, but mortality benefit remains unproven in randomized trials.
*Systematic review/meta-analysis plus retrospective cohort; Level 2a (OCEBM).

Citation

Ahn C, Lee GT, Kim JH, et al. Early vasopressin administration in septic shock. European Journal of Internal Medicine. 2026;151:106933. doi:10.1016/j.ejim.2026.106933

Background

Norepinephrine is first-line treatment for septic shock, but high doses may cause harm. Vasopressin can be added to reduce norepinephrine needs, but the best timing is uncertain.

Patients

Adults with septic shock receiving norepinephrine. The registry included emergency department patients from 20 Korean hospitals. The review excluded pediatric studies, reviews, case reports, studies without comparators, and studies lacking mortality outcomes.

Intervention

Early vasopressin, defined by study-specific timing or lower norepinephrine dose thresholds.

Control

Delayed vasopressin or norepinephrine alone.

Outcome

Primary: mortality. Secondary: intensive care unit length of stay, kidney dialysis-type support, and abnormal heart rhythms.

Follow-up Period

Usually 28 days or hospital discharge.

Results

The registry included 2,001 vasopressin-treated patients; the meta-analysis included 15 studies.

Finding Effect
Starting vasopressin at norepinephrine ≥0.5 mcg/kg/min increased 28-day mortality adjusted OR 2.15 (95% CI 1.59 to 2.92)
Starting 6–24 hours after norepinephrine increased 28-day mortality adjusted OR 1.59 (95% CI 1.21 to 2.11)
Observational studies: early vasopressin lowered mortality OR 0.71 (95% CI 0.60 to 0.84)
Randomized trials: early vasopressin reduced kidney support OR 0.46 (95% CI 0.26 to 0.81)

OR=odds ratio; CI=confidence interval.

Randomized trials did not show lower mortality: OR 0.84 (95% CI 0.66 to 1.07). Number needed to treat could not be calculated from reported pooled data.

Limitations

Most mortality evidence was observational, so sicker patients may have received later vasopressin. “Early” timing varied across studies. Randomized trials were limited and did not confirm survival benefit. Safety outcomes were incompletely reported.

Funding

Korean government health research grants; no reported funder role.

Clinical Application

Consider adding vasopressin before very high norepinephrine doses, but do not expect proven mortality benefit until better trials confirm timing.